FUNDAMENTALS |
MarketCap: |
17 057 mill
|
EPS: |
4.68
|
P/E: |
43.24
|
Earnings Date: |
Jul 25, 2024 |
SharesOutstanding: |
84.29 mill
|
Avg Daily Volume: |
0.809 mill
|
RATING
2024-05-08 |
A+
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Buy
|
|
Return On Asset: |
Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Buy
|
|
Price To Book: |
Neutral
|
|
QUARTER GROWTHS |
|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
2.80x
|
Company: PE 43.24 | sector: PE 15.43
|
PE RATIO: COMPANY / INDUSTRY |
0.39x
|
Company: PE 43.24 | industry: PE 109.92
|
DISCOUNTED CASH FLOW VALUE |
$297.63
(47.09%)
$95.28
|
Date: 2024-05-09
|
Expected Trading Range (DAY) |
$ 199.13 - 205.75
( +/- 1.63%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-04-30 | Anderson Kerrii B | Sell | 250 | Common Stock |
2024-05-02 | Anderson Kerrii B | Sell | 250 | Common Stock |
2024-04-30 | Eisenberg Glenn A | Buy | 10 229 | Common Stock |
2024-04-30 | Eisenberg Glenn A | Sell | 4 496 | Common Stock |
2024-04-30 | Eisenberg Glenn A | Sell | 10 229 | Performance Share Unit |
INSIDER POWER |
-11.09
|
Last
100 transactions |
Buy:
259 185 | Sell:
319 041 |
Forecast:
12:49 - $202.95
Live Trading Signals (every 1 min)
Forecast
1: 11:19 - $202.53
Forecast 2: 12:09 - $202.45
Forecast 3: 12:49 - $202.95
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$202.35 (0.37% )
|
Volume |
0.139 mill
|
Avg. Vol. |
0.809 mill
|
% of Avg. Vol |
17.17 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For LH
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.